With a global vision for innovation and profound industry insights, our founding team integrates visionary foresight into the full cycle of drug development, from research and clinical development to production and commercialization, and steers the company towards becoming a biopharmaceutical frontrunner in cancer and autoimmune diseases.
Jasmine Cui Ph.D.
Co-Founder Chairwoman and CEO
We founded InnoCare with the mission of saving and empowering lives by enabling patient’s access to the finest innovative drugs. As visionaries and trailblazers in the biopharmaceutical sector, we uphold the philosophy of ‘Science Drives Innovation for the Benefit of Patients’, dedicating ourselves to creating innovative drugs for cancer and autoimmune diseases. Recognizing that talent is the bedrock of biopharmaceutical innovation, InnoCare has always put talent at the top of its corporate development agenda. With a high-caliber talent team and top-tier innovation capabilities, we believe that InnoCare is well on track to become a world-class pharmaceutical company.
— Jasmine Cui Ph.D.
Xiangyang Chen Ph.D.
Sean Zhang MD
Kevin Gao Ph.D.
Mr. Xin Fu
Mr. Jeff Chen
Richard Liu Ph.D.
Vice President of Biology and Procurement
Charles Y. Wang Ph.D., DABT
Vice President of Drug Safety & DMPK
Renbin Zhao Ph.D.
Vice President of Clinical Development and Medical Research
Norman Kong Ph.D.
Vice President of Medicinal Chemistry
Boyan Zhang Ph.D.
Vice President of Biologics CMC
Manish Tandon Ph.D.
Vice President of Business Development
Carrie Zhou Ph.D.
Vice President of Medical Research
Scientific Advisory Board
Yigong Shi Ph.D.
InnoCare Co-founder & President of SAB
As China emerges as a formidable biopharmaceutical force, we've advanced in our capabilities, moving from producing best-in-class drugs to pioneering first-in-class medicines. We hope to independently develop more innovative drugs. Our innovation is fueled by an unwavering vision to improve human well-being, a goal which through our collective efforts is gradually becoming a reality.